

Reference:	FOI.15673.24
Subject:	Breast cancer treatment
Date of Request:	9 October 2024

Requested:

- How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
 - Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Abemaciclib + Fulvestrant
 - Alpelisib + Fulvestrant
 - Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
 - Aromatase Inhibitor as a single agent
 - Atezolizumab
 - Capecitabine as a single agent
 - Carboplatin + Paclitaxel
 - Eribulin as a single agent or in combination
 - Everolimus + Exemestane
 - Fulvestrant as a single agent
 - Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Palbociclib + Fulvestrant
 - Parp Inhibitors (Olaparib/Talazoparib)
 - Pembrolizumab
 - Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Ribociclib + Fulvestrant
 - Sacituzumab Govitecan
 - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
 - Transtuzumab deruxtecan
 - Trastuzumab as a single agent or in combination
 - Trastuzumab emtansine
 - Any other active systemic anti-cancer therapy
- Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested for question 1, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for the Aromatase Inhibitor as a single agent Systemic Anti-Cancer Therapy (SACT), the UHB would need to undertake a manual trawl of breast cancer patient records to identify any information that would fulfil your request, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds, as requested.

Where the figures in the table overleaf have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients that have been treated for breast cancer (any stage), with the listed SACTs, during the period 1 July to 30 September 2024.

Please note: - some of the therapies listed are recorded together on the ChemoCare system and are unable to be split; therefore, the information has been provided as recorded on the ChemoCare system.

Anti-cancer therapy	Number
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	27
Abemaciclib + Fulvestrant	See above
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	*
Aromatase Inhibitor as a single agent	Section 12 exemption applied
Atezolizumab	*
Capecitabine as a single agent	17
Carboplatin + Paclitaxel	7
Eribulin as a single agent or in combination	*
Everolimus + Exemestane	*
Fulvestrant as a single agent	26
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	34
Palbociclib + Fulvestrant	See above
Parp Inhibitors (Olaparib/Talazoparib)	*
Pembrolizumab	20
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	23
Ribociclib + Fulvestrant	See above
Sacituzumab Govitecan	*
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	44
Transtuzumab deruxtecan	7
Trastuzumab as a single agent or in combination	33
Trastuzumab emtansine	15

Any other active systemic anti-cancer therapy	*125
<p>*Patients may have had more than one SACT regimen)</p> <p>2. The UHB confirms that it is not currently participating in any clinical trials for the treatment of breast cancer.</p>	